MX2022001310A - Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo. - Google Patents

Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.

Info

Publication number
MX2022001310A
MX2022001310A MX2022001310A MX2022001310A MX2022001310A MX 2022001310 A MX2022001310 A MX 2022001310A MX 2022001310 A MX2022001310 A MX 2022001310A MX 2022001310 A MX2022001310 A MX 2022001310A MX 2022001310 A MX2022001310 A MX 2022001310A
Authority
MX
Mexico
Prior art keywords
phenyl
compounds
acetylamino
hydroxy
methyl
Prior art date
Application number
MX2022001310A
Other languages
English (en)
Inventor
Marta Maria Cifuentes-Garcia
Maria Cristina Garcia-Paredes
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2022001310A publication Critical patent/MX2022001310A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

La invención actual proporciona compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo, a composiciones farmacéuticas que comprenden los compuestos, a métodos de uso de los compuestos para tratar trastornos fisiológicos tales como cáncer.
MX2022001310A 2017-04-18 2019-10-17 Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo. MX2022001310A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17382207 2017-04-18

Publications (1)

Publication Number Publication Date
MX2022001310A true MX2022001310A (es) 2022-03-02

Family

ID=58606227

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019012428A MX2019012428A (es) 2017-04-18 2018-04-11 Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
MX2022001310A MX2022001310A (es) 2017-04-18 2019-10-17 Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019012428A MX2019012428A (es) 2017-04-18 2018-04-11 Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo.

Country Status (27)

Country Link
US (2) US11655214B2 (es)
EP (2) EP4039675A1 (es)
JP (2) JP7110232B2 (es)
KR (2) KR102575246B1 (es)
CN (2) CN110831927B (es)
AU (2) AU2018255191B2 (es)
BR (1) BR112019021867A2 (es)
CA (1) CA3060564A1 (es)
CO (1) CO2019012767A2 (es)
CR (1) CR20190519A (es)
CY (1) CY1125150T1 (es)
DK (1) DK3612519T3 (es)
ES (1) ES2906847T3 (es)
HR (1) HRP20220263T1 (es)
HU (1) HUE057745T2 (es)
IL (2) IL270005B (es)
LT (1) LT3612519T (es)
MX (2) MX2019012428A (es)
PH (1) PH12019502363A1 (es)
PL (1) PL3612519T3 (es)
PT (1) PT3612519T (es)
RS (1) RS62933B1 (es)
SA (1) SA519410320B1 (es)
SG (1) SG11201909680UA (es)
SI (1) SI3612519T1 (es)
WO (1) WO2018194885A1 (es)
ZA (1) ZA201906811B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018255191B2 (en) 2017-04-18 2022-04-21 Eli Lilly And Company Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
EP3775171B1 (en) * 2018-03-26 2024-01-03 Icahn School of Medicine at Mount Sinai Methods of treating minimal residual cancer
WO2021041973A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting compounds
JP2022546414A (ja) 2019-08-29 2022-11-04 ヒベルセル， インコーポレイテッド Ｐｅｒｋ阻害ピロロピリミジン化合物
WO2021041970A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting imidazolopyrazine compounds
WO2021041976A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting indolinyl compounds
WO2021231782A1 (en) * 2020-05-13 2021-11-18 Hibercell, Inc. Perk inhibitors for treating viral infections
WO2021231788A1 (en) * 2020-05-13 2021-11-18 Hibercell, Inc. Perk inhibiting pyrrolopyrimidine compounds to treat viral infections
CN113234029B (zh) * 2021-05-25 2022-03-22 白银康寓信生物科技有限公司 一种2-氨基-3,5-二卤代吡嗪的合成方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
AU748884B2 (en) 1997-03-19 2002-06-13 Abbott Gmbh & Co. Kg Pyrrolo(2,3d)pyrimidines and their use as tyrosine kinase inhibitors
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
CL2004001834A1 (es) * 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
PE20070427A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
KR20080040027A (ko) * 2005-09-02 2008-05-07 아스테라스 세이야쿠 가부시키가이샤 Ｒｏｃｋ 억제제로서 아미드 유도체
DK2602623T3 (en) 2008-02-25 2015-11-09 Nestec Sa METHOD OF DETECTING INTRACELLULAR TRUNCTED RECEPTORS
WO2010080992A1 (en) 2009-01-09 2010-07-15 The Trustees Of The University Of Pennsylvania Regulators of the interferon-alpha receptor 1 (ifnar1) chain of the interferon receptor
BR112012024380A2 (pt) 2010-03-25 2015-09-15 Glaxosmithkline Llc compostos químicos
WO2014170706A1 (en) 2013-04-15 2014-10-23 Università Degli Studi Di Bari Galloyl benzamide-based compounds as jnk modulators
WO2015056180A1 (en) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
JP6493218B2 (ja) 2013-11-08 2019-04-03 小野薬品工業株式会社 ピロロピリミジン誘導体
WO2015136463A1 (en) 2014-03-11 2015-09-17 Glaxosmithkline Intellectual Property (No.2) Limited Chemical compounds acting as perk inhibitors
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
WO2016075224A1 (en) 2014-11-14 2016-05-19 Nerviano Medical Sciences S.R.L. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
GB201508747D0 (en) 2015-05-21 2015-07-01 Univ Edinburgh Compounds
AU2016297754A1 (en) 2015-07-24 2018-02-15 Blueprint Medicines Corporation Compounds useful for treating disorders related to KIT and PDGFR
ES2965081T3 (es) 2016-07-07 2024-04-11 Daewoong Pharmaceutical Co Ltd Derivados 4-aminopirazolo[3,4-d]pirimidinil-azabiciclo y composición farmacéutica que comprende dichos derivados
CN109789135A (zh) 2016-07-20 2019-05-21 葛兰素史密斯克莱知识产权发展有限公司 作为perk抑制剂的异喹啉衍生物
CN106748989B (zh) 2016-11-14 2020-03-17 西安交通大学 一种具有抗肿瘤活性的二芳基脲类化合物及其制备方法和应用
EP3656382A1 (en) 2017-01-30 2020-05-27 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
AU2018255191B2 (en) 2017-04-18 2022-04-21 Eli Lilly And Company Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
EP3709998A4 (en) 2017-11-14 2021-07-07 Children's Medical Center Corporation NEW IMIDAZOPYRIMIDINE COMPOUNDS AND THEIR USES
EP3492454A1 (en) 2017-11-30 2019-06-05 Step Pharma S.A.S. Compounds
EP3775171B1 (en) 2018-03-26 2024-01-03 Icahn School of Medicine at Mount Sinai Methods of treating minimal residual cancer
AU2019297428C1 (en) 2018-07-06 2023-03-23 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
US20220040183A1 (en) 2018-10-01 2022-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inhibitors of stress granule formation for targeting the regulation of immune responses

Also Published As

Publication number Publication date
CN117510405A (zh) 2024-02-06
US20210114985A1 (en) 2021-04-22
IL270005B (en) 2022-01-01
CO2019012767A2 (es) 2020-04-01
LT3612519T (lt) 2022-03-25
CN110831927B (zh) 2023-07-14
CY1125150T1 (el) 2023-06-09
PL3612519T3 (pl) 2022-05-02
KR20190140966A (ko) 2019-12-20
KR20230129627A (ko) 2023-09-08
BR112019021867A2 (pt) 2020-05-26
SI3612519T1 (sl) 2022-04-29
HUE057745T2 (hu) 2022-06-28
RS62933B1 (sr) 2022-03-31
HRP20220263T1 (hr) 2022-04-29
JP7331212B2 (ja) 2023-08-22
WO2018194885A1 (en) 2018-10-25
IL288822A (en) 2022-02-01
DK3612519T3 (da) 2022-03-07
MX2019012428A (es) 2022-01-28
AU2022206702A1 (en) 2022-08-11
RU2019136694A3 (es) 2021-05-19
JP2022141835A (ja) 2022-09-29
ZA201906811B (en) 2021-01-27
EP3612519B1 (en) 2021-12-01
SG11201909680UA (en) 2019-11-28
PH12019502363A1 (en) 2020-12-07
EP4039675A1 (en) 2022-08-10
ES2906847T3 (es) 2022-04-20
RU2019136694A (ru) 2021-05-18
JP7110232B2 (ja) 2022-08-01
CA3060564A1 (en) 2018-10-25
US11655214B2 (en) 2023-05-23
SA519410320B1 (ar) 2022-05-08
CN110831927A (zh) 2020-02-21
EP3612519A1 (en) 2020-02-26
KR102575246B1 (ko) 2023-09-06
AU2018255191B2 (en) 2022-04-21
IL288822B2 (en) 2023-06-01
JP2021517555A (ja) 2021-07-26
AU2022206702B2 (en) 2024-04-11
CR20190519A (es) 2020-03-06
US20230373922A1 (en) 2023-11-23
PT3612519T (pt) 2022-02-22
AU2018255191A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
MX2018014154A (es) Polinucleotidos moduladores.
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
PH12020550901A1 (en) Macrocyclic compounds for treating disease
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA033163B1 (ru) Ингибиторы глутаминазы
MX2015012056A (es) Inhibidores de indolamina-2,3-dioxigenasa (ido).
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
PH12019500196A1 (en) Compounds and compositions and uses thereof
NZ761519A (en) Nlrp3 modulators
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2017009608A (es) Compuestos anticancerigenos.
IN2013MU03118A (es)
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
JO3621B1 (ar) مركبات وتركيبات على هيئة عوامل مساعدة لمستقبل 7 يشبه toll
GB2553684A8 (en) Ethynylxanthines, preparation and use for cancer treatment